What is Bombesin?

A 14-amino-acid peptide first found in frog skin; its analogs are studied as imaging tracers for some cancers.

Bombesin in the library · · Human Trials · What are peptides?

10 registered trials · 35 indexed papers · 103 human / 304 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

A 14-amino-acid peptide first found in frog skin; its analogs are studied as imaging tracers for some cancers.

Type: Peptide.

Definition (National Library of Medicine)

“A tetradecapeptide originally obtained from the skins of toads Bombina bombina and B. variegata. It is also an endogenous neurotransmitter in many animals including mammals. Bombesin affects vascular and other smooth muscle, gastric secretion, and renal circulation and function.”

  • MeSH: Bombesin

Human research

The registered human trials and peer-reviewed human studies linked below are listed from ClinicalTrials.gov and PubMed. A study is linked only when Bombesin is one of its interventions, or is named in the study title or subject headings.

Listing a study does not mean it showed a benefit, and it is not medical advice.

Registered human trials (10)

Peer-reviewed studies (35)

PaperAuthorsJournalYearType
Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II studyBeheshti M et al.European radiology2023Clinical Trial, Phase II
MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of (68)Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST PatientsGruber L et al.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2020Clinical Trial, Phase II
Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate CancerTouijer KA et al.European urology oncology2019Clinical Trial
68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma PatientsZhang J et al.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2016Clinical Trial
Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to menWieser G et al.Theranostics2014Clinical Trial
Application of (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14) SPECT/CT in prostate cancer patients: a first-in-man studyAnanias HJ et al.Nuclear medicine and biology2013Clinical Trial
Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy menRoivainen A et al.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2013Clinical Trial
Gastrin-releasing peptide receptor antagonism induces protection from lethal sepsis: involvement of toll-like receptor 4 signalingPetronilho F et al.Molecular medicine (Cambridge, Mass.)2012Controlled Clinical Trial
Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patientsReitman ML et al.Journal of clinical pharmacology2012Randomized Controlled Trial
Targeted imaging of gastrin-releasing peptide receptors with 99mTc-EDDA/HYNIC-[Lys3]-bombesin: biokinetics and dosimetry in womenSantos-Cuevas CL et al.Nuclear medicine communications2008Clinical Trial
A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignanciesSchwartsmann G et al.Investigational new drugs2006Clinical Trial, Phase I
Detection of colon cancer with 99mTc-labeled bombesin derivative (99mTc-leu13-BN1)Scopinaro F et al.Cancer biotherapy & radiopharmaceuticals2004Clinical Trial
Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancerDe Vincentis G et al.Cancer biotherapy & radiopharmaceuticals2004Clinical Trial
99MTC [13LEU] bombesin and a new gamma camera, the imaging probe, are able to guide mammotome breast biopsySoluri A et al.Anticancer research2003Clinical Trial
Phase I trial of technetium [Leu13] bombesin as cancer seeking agent: possible scintigraphic guide for surgery?De Vincentis G et al.Tumori2002Clinical Trial, Phase I
Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignanciesVan de Wiele C et al.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2001Clinical Trial
Regulation of gastric function by endogenous gastrin releasing peptide in humans: studies with a specific gastrin releasing peptide receptor antagonistHildebrand P et al.Gut2001Controlled Clinical Trial
Blockade of GRP receptors inhibits gastric emptying and gallbladder contraction but accelerates small intestinal transitDegen LP et al.Gastroenterology2001Controlled Clinical Trial
Effect of bombesin on esophageal motility in humansMasclee AA et al.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus1999Randomized Controlled Trial
Effect of acute hyperglycemia on basal and bombesin-stimulated pancreaticobiliary secretion in humansLam WF et al.Pancreas1998Randomized Controlled Trial
Obese women are less sensitive for the satiety effects of bombesin than lean womenLieverse RJ et al.European journal of clinical nutrition1998Randomized Controlled Trial
Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancerKelley MJ et al.Chest1997Clinical Trial, Phase II
Bombesin-like peptides and satietyGibbs J et al.Appetite1995Controlled Clinical Trial
Significant satiety effect of bombesin in lean but not in obese subjectsLieverse RJ et al.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity1994Controlled Clinical Trial
Bombesin reduces food intake in lean man by a cholecystokinin-independent mechanismLieverse RJ et al.The Journal of clinical endocrinology and metabolism1993Controlled Clinical Trial
Bombesin reduces food intake after a preload in man by a cholecystokinin-independent mechanismLieverse RJ et al.Clinical science (London, England : 1979)1993Randomized Controlled Trial
Effect of duodenal juice on bombesin-stimulated cholecystokinin release during loxiglumide administration in manJebbink MC et al.European journal of clinical investigation1993Randomized Controlled Trial
Effect of loxiglumide on basal and gastrin- and bombesin-stimulated gastric acid and serum gastrin levelsJebbink MC et al.Gastroenterology1992Randomized Controlled Trial
Effect of parietal cell vagotomy and cholinergic blockade on gastrin release in man induced by gastrin-releasing peptideSjövall M et al.Digestion1990Clinical Trial
Oncogenes evoke new cancer therapiesMarx JScience (New York, N.Y.)1990Clinical Trial

More cited research

Conditions researched

Related compounds

FAQ

What is Bombesin?

A 14-amino-acid peptide first found in frog skin; its analogs are studied as imaging tracers for some cancers.

How many registered human trials study Bombesin?

The PeptideWhiz trial index lists 10 registered trials for Bombesin, the most recent from 2022.

How much published research exists on Bombesin?

The PeptideWhiz paper index links 35 PubMed papers to Bombesin; by study type, 103 human and 304 animal studies.

Which conditions is Bombesin researched for?

Delayed gastric emptying on GLP-1 medicines, Gallbladder and gallstones, Immune system (general), Insulin resistance, prediabetes & type 2 diabetes, Post-surgical inflammation and surgery recovery.

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).